KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,548,647 | -53.8% | 1,820,462 | 0.0% | 0.01% | -56.5% |
| Q2 2023 | $5,516,000 | -51.5% | 1,820,462 | 0.0% | 0.02% | -56.6% |
| Q1 2023 | $11,377,888 | +2.5% | 1,820,462 | 0.0% | 0.05% | -5.4% |
| Q4 2022 | $11,104,818 | -49.0% | 1,820,462 | 0.0% | 0.06% | -44.0% |
| Q3 2022 | $21,755,000 | -5.2% | 1,820,462 | 0.0% | 0.10% | -4.8% |
| Q2 2022 | $22,956,000 | +12.0% | 1,820,462 | 0.0% | 0.10% | +26.5% |
| Q1 2022 | $20,498,000 | -36.5% | 1,820,462 | 0.0% | 0.08% | -10.8% |
| Q4 2021 | $32,259,000 | -23.0% | 1,820,462 | 0.0% | 0.09% | -19.1% |
| Q3 2021 | $41,907,000 | -1.1% | 1,820,462 | 0.0% | 0.12% | -10.2% |
| Q2 2021 | $42,380,000 | -27.3% | 1,820,462 | -2.8% | 0.13% | -26.4% |
| Q1 2021 | $58,332,000 | -21.7% | 1,872,023 | 0.0% | 0.17% | -15.1% |
| Q4 2020 | $74,469,000 | – | 1,872,023 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |